Cancer 2035: A Roadmap for the Future

Events

Feb 23, 2026

Cancer 2035: A Roadmap for the Future
Date: February 23–24, 2026
Location: Washington, DC
https://milkeninstitute.org/cancer-2035-roadmap-future

To download the presentation, please click the link below.
Download Presentation (PDF)

Contact us at

+1-844-MY NK CELLS (+1-844-696-5235)

Visit Newsroom

Solutions for Patients

ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Next-generation adenovirus-vectored anti-cancer vaccines make appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us